98%
921
2 minutes
20
Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are correlated with high morbidity and mortality rates. Guidelines that consider local epidemiologic data are fundamental for identifying optimal treatment strategies. However, Korea has no HAP/VAP guidelines. This study was conducted by a committee of nine experts from the Korean Academy of Tuberculosis and Respiratory Diseases Respiratory Infection Study Group using the results of Korean HAP/VAP epidemiologic studies. Eleven key questions for HAP/VAP diagnosis and treatment were addressed. The Convergence of Opinion on Suggestions and Evidence (CORE) process was used to derive suggestions, and evidence levels and recommendation grades were in accordance with the Grading of Recommendations Assessment Development and Evaluation (GRADE) methodology. Suggestions were made for the 11 key questions pertinent to diagnosis, biomarkers, antibiotics, and treatment strategies for adult patients with HAP/VAP. Using the CORE process and GRADE methodology, the committee generated a series of recommendations for HAP/VAP diagnosis and treatment in the Korean context.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704733 | PMC |
http://dx.doi.org/10.4046/trd.2024.0135 | DOI Listing |
Health Expect
October 2025
Murdoch Children's Research Institute, Parkville, Victoria, Australia.
Introduction: Despite high coverage of routine childhood vaccines, uptake of the human papillomavirus (HPV) vaccine in the Pacific Island nation of Tonga has been slow. Culturally appropriate communication resources on the importance, safety, and effectiveness of the HPV vaccine are critical to support acceptance and uptake. To develop these resources, it is important to understand what people want to know.
View Article and Find Full Text PDFCalcif Tissue Int
September 2025
Department of Endocrinology, Post-Graduate Institute of Medical Education and Research (PGIMER), 001, Nehru Extension Block, Chandigarh, India.
Rare diseases, defined by the 2002 Rare Disease Act, affect fewer than 5 in 10,000 individuals. Rare metabolic bone diseases (MBDs), such as osteogenesis imperfecta, hypophosphatasia, osteopetrosis, and other unclassified disorders, can disrupt bone development and remodeling, posing diagnostic and management challenges. This study analyzed data from the rarembd.
View Article and Find Full Text PDFJ Robot Surg
September 2025
Department of Urology, Rennes University Hospital, Rennes, France.
The surgical approach of ureteral stricture has changed dramatically over the past 15 years with the rise of robotic upper urinary tract reconstruction. This study aimed to evaluate the outcomes of all robotic ureteral reconstructions performed at a single academic center for ureteral stricture and to assess the predictive factors of stricture recurrence. The charts of all patients who underwent robot-assisted ureteral reconstruction between 2013 and 2024 at a single academic center were retrospectively reviewed.
View Article and Find Full Text PDFPituitary
September 2025
Facoltà Di Medicina E Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction: Pituitary adenomas (PAs) are generally benign neoplasms, though in rare cases may exhibit aggressive behavior. In 2024, the PANOMEN-3 workshop released a new clinical-pathological classification. The objective of this study was to examine the potential of the PANOMEN-3 classification to predict prognosis of PAs and guide treatment in our single center cohort of patients with PAs.
View Article and Find Full Text PDFTransfusion
September 2025
Department of Pathology and Molecular Medicine, Kingston Health Sciences Centre and Queen's University, Kingston, Canada.
Background: There is limited high-quality evidence to guide plasma transfusion, and plasma transfusion practices remain variable.
Study Design And Methods: This is a retrospective cohort study that included adult medical and intensive care unit (ICU) inpatients (age ≥ 18 years) admitted to 23 hospitals in Canada between January 1, 2017, and December 31, 2022, when both whole blood derived (~290 mL) and apheresis plasma (~250 mL) were available for transfusion. Nine additional hospital sites with missing plasma data or coagulation testing were excluded.